:: Volume 19, Issue 2 (4-2021) ::
Int J Radiat Res 2021, 19(2): 479-482 Back to browse issues page
Feasibility of stereotactic ablative reirradiation in breast cancer patient undergoing palbociclib: a case report
V. Nardone , A. Reginelli , C. Vitale , M.G. Calvanese , P. Correale , R. Grassi , S. Falivene , A. Sangiovanni , S. Cappabianca , C. Guida
Unit of Radiation Oncology, Ospedale del Mare, Naples, Italy , v.nardone@hotmail.it
Abstract:   (1632 Views)
Background: We report a case of a metastatic breast cancer woman undergoing therapy with fulvestrant and palbociclib that was successfully treated with thoracic stereotactic ablative radiation therapy (SABR) for a hilar lymph node metastasis. Case Description: The patient began the radiation treatment in the week off of the palbociclib and reported no acute toxicity. The CT scan showed acute pneumonia 60 days after RT although the patient reported no symptomatology. In addition, the subsequent PET/TC scan performed six months after RT exhibited a complete response of the irradiated lesion. Conclusion: The use of SABR in patients undergoing cyclin inhibitors appears to be potentially effective although the association must be further studied to investigate the toxicities.
Keywords: Cycline inhibitors, breast cancer, SABR, stereotactic radiation therapy, reirradiation.
Full-Text [PDF 1401 kb]   (572 Downloads)    
Type of Study: Case Report | Subject: Medical Physics



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 2 (4-2021) Back to browse issues page